In TNBC models, BETi JQ1 disrupts enhancer remodeling induced by MEKi trametinib, blocks kinome reprogramming and suppresses tumor growth; in lung cancer models, JQ1 can overcome MEK and TBK1 inhibition resistance via suppressing adaptive activation of YAP1/TAZ and IGF1/IGF1R signaling 108. This evidence concerns the gene IGF1R and neoplasm.